Business
Ligand Reports First Quarter 2026 Financial Results
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecas
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"image","alt":"Ligand Pharmaceuticals","displaySize":"","headline":null,"caption":"Ligand Pharmaceuticals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":105,"url":"https://media.zenfs.com/en/globenewswire.com/e824ed3c4822e04f01467c6db4017595"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RxGj7s7LJi3M86PIFXFxrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/e824ed3c4822e04f01467c6db4017595","width":300,"height":105},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/RxGj7s7LJi3M86PIFXFxrw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Nw--/https://media.zenfs.com/en/globenewswire.com/e824ed3c4822e04f01467c6db4017595","width":300,"height":105}},"lazy":false},{"type":"text","content":"First quarter performance driven by strong year-over-year royalty revenue growth of 56%","length":92,"tagName":"p"},{"type":"text","content":"Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition","length":148,"tagName":"p"},{"type":"text","content":"Conference call begins at 8:30 a.m. Eastern Time today","length":54,"tagName":"p"},{"type":"text","content":"JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions.","length":365,"tagName":"p"},{"type":"text","content":"“The first few months of 2026 have already proven to be highly productive and transformative for Ligand,” said Todd Davis, CEO of Ligand. “In April, we announced a definitive agreement to acquire XOMA Royalty Corporation (“XOMA Royalty” or “XOMA”), a highly complementary business that we expect to accelerate both near and long-term growth. Upon closing, the transaction will add more than 120 commercial, clinical and preclinical-stage assets to our royalty portfolio, including seven commercial assets and 14 late-stage programs, and meaningfully diversify Ligand across therapeutic areas, stages of development, and biopharma partners. We were also pleased to see the full FDA approval of Filspari in focal segmental glomerulosclero...